Phase II study of auto-gamma/delta T cell therapy for multiple myeloma.
Phase 2
- Conditions
- Multiple myeloma
- Registration Number
- JPRN-UMIN000007878
- Lead Sponsor
- Japanese Red Cross Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: - Uncontrolled infections; - Continuous systemic administration of steroids; - Active autoimmune diseases; - Pregnant, to be pregnant, or nursing mothers; - Active enteritis and/or gastrointestinal bleeding; - Other cancers;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method